NCT07271342Recruiting
Observational RegIstry of Effectiveness and Safety of teNecTeplase in reAl worLd Settings in China
Observational Registry of Effectiveness and Safety of Tenecteplase in Real World Settings in China-ORIENTAL
Source: ClinicalTrials.gov · Last updated 6 Jan 2026
Brief summary (registry, in English)
The ORIENTAL study is a prospective, multicenter, continuously enrolled real-world cohort designed to evaluate the effectiveness and safety of intravenous tenecteplase for acute ischemic stroke (AIS) in routine clinical practice across China. Approximately 10,000 patients from about 200 hospitals will be included. Eligible adults with imaging-confirmed AIS who receive tenecteplase as part of standard care will be consecutively enrolled and followed through 90 days. The study will describe patient characteristics, treatment processes, functional outcomes, and safety events, and will also explore inter-hospital variability and subgroup differences to support quality improvement and guide nationwide implementation of tenecteplase therapy.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 10000 (estimated)
- First submitted
- 28 Nov 2025
- Start date
- 30 Nov 2025
- Primary completion date
- 31 Mar 2029
- Lead sponsor
- Beijing Tiantan Hospital
- Diseases
- Stroke
- NCT number
- NCT07271342
What you commit to
- Study type: Observational
- Planned participants: 10000
- From 30 Nov 2025 to the primary completion date, 31 Mar 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Received reperfusion therapy prior to the hospital admission (e.g., intravenous thrombolysis prior to admission);
Other
- Participating in any clinical trials where the intervention may affect the outcomes of this study.
Who the study is looking for
- Adults aged 18 years or older;
- Diagnosed with acute ischemic stroke confirmed by imaging (CT or MRI);
- Treated with intravenous tenecteplase at the participating institution;
- Provided written informed consent, signed by the patient or their legally authorized representative;
- Capable of completing follow-up assessments.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Beijing Tiantan Hospital,Capital Medical University Coordinator of this site? Confirm its status | Beijing | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.